Core Measures
27 views | +0 today
Follow
Your new post is loading...
Your new post is loading...
Rescooped by Heather Byrd from Caring for the Patient with Atrial Fibrillation
Scoop.it!

Analysis Gives Edge to Pradaxa Over Xarelto

Analysis Gives Edge to Pradaxa Over Xarelto | Core Measures | Scoop.it
The highest approved dose of dabigatran (Pradaxa) was better at reducing the risk of stroke or systemic embolism in patients with atrial fibrillation than rivaroxaban (Xarelto), an indirect comparison...

Via Steve S Ryan, PhD
more...
No comment yet.
Rescooped by Heather Byrd from Joeygiggles Health Topics
Scoop.it!

Nebivolol: New Therapy Update : Cardiology in Review

Nebivolol is a [beta]-blocker under U.S. Food and Drug Administration review for the treatment of hy (New Therapy Update: Nebivolol: New Therapy Update: Nebivolol is a [beta]-blocker under U.S.

Via Joseph Aquilino
more...
No comment yet.
Rescooped by Heather Byrd from Heart and Vascular Health
Scoop.it!

β-Blocker Use & Clinical Outcomes in Stable Outpatients

β-Blocker Use & Clinical Outcomes in Stable Outpatients | Core Measures | Scoop.it

My comment: Another icon of medicine is challenged!  If you've had a heart attack (MI), it is the standard of care now to be treated with beta blocker medicines like metoprolol or atenolol indefinitely.  Physicians are graded for their use of beta blockers.  If these are not used with adequate frequency the physician is considered to not be practicing evidence based medicine.  This large study challenges the curent recommendations.  This data suggests no benefit with a history of MI from long ago and possibly harm in patients with only risk factors. How long will it take for guidelines to consider this new data is unknown?

 

=================

Reduction of Atherothrombosis for Continued Health (REACH) registry who were divided into 3 cohorts: known prior MI (n = 14 043), known CAD without MI (n = 12 012), or those with CAD risk factors only (n = 18 653).  The primary outcome was a composite of cardiovascular death, nonfatal MI, or nonfatal stroke.

Results: Among the 44,708 patients, 21,860 were included in the propensity score–matched analysis. With a median follow-up of 44 months, event rates were not significantly different in patients with β-blocker use compared with those without β-blocker use. In the cohort with CAD risk factors only, the event rates were higher for the primary outcome with β-blocker use.  However, in those with recent MI (≤1 year), β-blocker use was associated with a lower incidence of the secondary outcome.

Conclusion In this observational study of patients with either CAD risk factors only, known prior MI, or known CAD without MI, the use of β-blockers was not associated with a lower risk of composite cardiovascular events.


Via Seth Bilazarian, MD
more...
No comment yet.
Rescooped by Heather Byrd from News You Can Use - NO PINKSLIME
Scoop.it!

Antibiotic-resistant bacterial infections continue to rise: Just how inept is the conventional medical industry?

Antibiotic-resistant bacterial infections continue to rise: Just how inept is the conventional medical industry? | Core Measures | Scoop.it
Antibiotic-resistant bacterial infections continue to rise: Just how inept is the conventional medical industry?

Via #BBBundyBlog #NOMORELIES Tom Woods #Activist Award #Scoopiteer >20,000 Sources >250K Connections http://goo.gl/ruHO3Q
more...
No comment yet.
Scooped by Heather Byrd
Scoop.it!

Many Docs Wrongly Prescribe Powerful Antibiotics: Study – WebMD

Many Docs Wrongly Prescribe Powerful Antibiotics: Study – WebMD | Core Measures | Scoop.it
Using these drugs incorrectly, such as for viruses, adds to problem of drug-resistant bacteria.
Heather Byrd's insight:

Over prescribing of antibiotics can be deadly

more...
No comment yet.
Rescooped by Heather Byrd from Heart and Vascular Health
Scoop.it!

New Blood Thinner: Xarelto for Atrial Fibrillation (AF) and Stroke Prevention

Xarelto (Rivaroxaban) is a new alternative for prevention of stroke for patients with atrial fibrillation. With its introduction, we now have the oldest option for patients, Coumadin (Warfarin) and another new anticoagulant treatment Pradaxa (Dabigatran) as options available to reuduce stroke (CVA) risk.  Drs Srivistava and Bilazarian discuss the newest entrant and review the data for patients on the series Matters of the Heart produced by Haverhill Community Television and Pentucket Cardiology.


Via Seth Bilazarian, MD
more...
No comment yet.
Rescooped by Heather Byrd from Cardiovascular Disease: PHARMACO-THERAPY
Scoop.it!

Beta-blockers are good for patients with heart failure - Toronto NewsFIX

Beta-blockers are good for patients with heart failure - Toronto NewsFIX | Core Measures | Scoop.it
Toronto NewsFIX
Beta-blockers are good for patients with heart failure
Toronto NewsFIX
A trial shows that beta-blocker therapy is well tolerated and effective for patients with heart failure.

Via Aviva Lev-Ari, PhD, RN
more...
No comment yet.
Scooped by Heather Byrd
Scoop.it!

Patient education may be key to reducing hospital-acquired infections

Patient education may be key to reducing hospital-acquired infections | Core Measures | Scoop.it
Despite a nation-wide effort to increase adherence to hand-washing, hospitals continue to be a breeding ground for dangerous, preventable infections.
Heather Byrd's insight:

Education while in the hospital is key for infection prevention

more...
No comment yet.
Scooped by Heather Byrd
Scoop.it!

DVT Symptoms Pictures: Leg Pain, Embolism, Causes, and Treatments

DVT Symptoms Pictures: Leg Pain, Embolism, Causes, and Treatments | Core Measures | Scoop.it
A painful, swollen leg may be one sign of a dangerous clot. WebMD's slideshow covers the symptoms and treatments for deep vein thrombosis (DVT).
Heather Byrd's insight:

Important to teach

more...
No comment yet.